Is granisetron the ‘preferred’ antiemetic?

    loading  Checking for direct PDF access through Ovid

Abstract

SmithKline Beecham is claiming that clinical differences may exist between 3 frequently-used antiemetics. This claim follows the completion of 3 studies in which cancer patients identified the 5HT3 antiemetic they ‘preferred’. Granisetron, SmithKline Beecham's drug, appeared to come out on top. Discussions on the relevance of these trials took place at a SmithKline Beecham-sponsored symposium held during the 7th European Conference on Clinical Oncology (ECCO) in Jerusalem, Israel, in November.

Related Topics

    loading  Loading Related Articles